Literature DB >> 15897154

MPTP and SNpc DA neuronal vulnerability: role of dopamine, superoxide and nitric oxide in neurotoxicity. Minireview.

V Jackson-Lewis1, R J Smeyne.   

Abstract

Parkinson disease (PD) is a common neurodegenerative disease of unknown origin that is characterized, mainly, by a significant reduction in the number of dopamine neurons in the substantia nigra pars compacta (SNpc) of the brain and a dramatic reduction in dopamine levels in the corpus striatum. For reasons that we do not know, the dopamine neuron seems to be more vulnerable to damage than any other neuron in the brain. Although hypotheses of damage to the dopamine neuron include oxidative stress, growth factor decline, excitotoxicity, inflammation in the SNpc and protein aggregation, oxidative stress in the nigrostriatal dopaminergic system garners a significant amount of attention. In the oxidative stress hypothesis of PD, superoxide, nitric oxide and dopamine all conspire to create an environment that can be detrimental to the dopamine neuron. MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), the tool of choice for investigations into the mechanisms involved in the death of dopamine neurons in PD, has been used extensively in attempts to sort out what happens in and around the dopamine neuron. Herein, we review the roles of dopamine, superoxide and nitric oxide in the demise of the dopamine neuron in the MPTP model of PD as it relates to the death of the dopamine neuron noted in PD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15897154     DOI: 10.1007/bf03036449

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  76 in total

1.  NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.

Authors:  Du-Chu Wu; Peter Teismann; Kim Tieu; Miquel Vila; Vernice Jackson-Lewis; Harry Ischiropoulos; Serge Przedborski
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-29       Impact factor: 11.205

2.  Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease.

Authors:  Y Mizuno; S Ohta; M Tanaka; S Takamiya; K Suzuki; T Sato; H Oya; T Ozawa; Y Kagawa
Journal:  Biochem Biophys Res Commun       Date:  1989-09-29       Impact factor: 3.575

3.  The parkinsonian toxin MPTP: action and mechanism.

Authors:  Serge Przedborski; Vernice Jackson-Lewis; Ruth Djaldetti; Gabriel Liberatore; Miquel Vila; Slobodanka Vukosavic; Gabrielle Almer
Journal:  Restor Neurol Neurosci       Date:  2000       Impact factor: 2.406

4.  FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells.

Authors:  S Hunot; N Dugas; B Faucheux; A Hartmann; M Tardieu; P Debré; Y Agid; B Dugas; E C Hirsch
Journal:  J Neurosci       Date:  1999-05-01       Impact factor: 6.167

5.  Levodopa prolongs life expectancy and is non-toxic to substantia nigra.

Authors:  A H Rajput
Journal:  Parkinsonism Relat Disord       Date:  2001-10       Impact factor: 4.891

6.  MPTP, MPP+ and mitochondrial function.

Authors:  W J Nicklas; S K Youngster; M V Kindt; R E Heikkila
Journal:  Life Sci       Date:  1987-02-23       Impact factor: 5.037

Review 7.  Pathogenic role of glial cells in Parkinson's disease.

Authors:  Peter Teismann; Kim Tieu; Oren Cohen; Dong-Kug Choi; Du Chu Wu; Daniel Marks; Miquel Vila; Vernice Jackson-Lewis; Serge Przedborski
Journal:  Mov Disord       Date:  2003-02       Impact factor: 10.338

8.  Protective effects of neuronal nitric oxide synthase inhibitor in mouse brain against MPTP neurotoxicity: an immunohistological study.

Authors:  Hijiri Watanabe; Yasuko Muramatsu; Rumiko Kurosaki; Mari Michimata; Mitsunobu Matsubara; Yutaka Imai; Tsutomu Araki
Journal:  Eur Neuropsychopharmacol       Date:  2004-03       Impact factor: 4.600

9.  Astrocytes convert the parkinsonism inducing neurotoxin, MPTP, to its active metabolite, MPP+.

Authors:  B R Ransom; D M Kunis; I Irwin; J W Langston
Journal:  Neurosci Lett       Date:  1987-04-10       Impact factor: 3.046

10.  Dynamics of expression of the mRNA for cytokines and inducible nitric synthase in a murine model of the Parkinson's disease.

Authors:  Agnieszka Ciesielska; Ilona Joniec; Adam Przybyłkowski; Grazyna Gromadzka; Iwona Kurkowska-Jastrzebska; Anna Członkowska; Andrzej Członkowski
Journal:  Acta Neurobiol Exp (Wars)       Date:  2003       Impact factor: 1.579

View more
  34 in total

Review 1.  Potential future neuroprotective therapies for neurodegenerative disorders and stroke.

Authors:  Rawan Tarawneh; James E Galvin
Journal:  Clin Geriatr Med       Date:  2010-02       Impact factor: 3.076

2.  Effects of age, gender, and gonadectomy on neurochemistry and behavior in animal models of Parkinson's disease.

Authors:  Andrea Tamás; Andrea Lubics; István Lengvári; Dóra Reglodi
Journal:  Endocrine       Date:  2006-04       Impact factor: 3.633

3.  Distinct mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine resistance revealed by transcriptome mapping in mouse striatum.

Authors:  R Pattarini; Y Rong; C Qu; J I Morgan
Journal:  Neuroscience       Date:  2008-07-08       Impact factor: 3.590

4.  The catecholaminergic RCSN-3 cell line: a model to study dopamine metabolism.

Authors:  Irmgard Paris; Jorge Lozano; Sergio Cardenas; Carolina Perez-Pastene; Katherine Saud; Patricio Fuentes; Pablo Caviedes; Alexies Dagnino-Subiabre; Rita Raisman-Vozari; Takeshi Shimahara; John P Kostrzewa; David Chi; Richard M Kostrzewa; Raul Caviedes; Juan Segura-Aguilar
Journal:  Neurotox Res       Date:  2008 May-Jun       Impact factor: 3.911

5.  The parkinsonian mimetic, MPP+, specifically impairs mitochondrial transport in dopamine axons.

Authors:  Jeong Sook Kim-Han; Jo Ann Antenor-Dorsey; Karen L O'Malley
Journal:  J Neurosci       Date:  2011-05-11       Impact factor: 6.167

Review 6.  Potential of animal models for advancing the understanding and treatment of pain in Parkinson's disease.

Authors:  Yazead Buhidma; Katarina Rukavina; Kallol Ray Chaudhuri; Susan Duty
Journal:  NPJ Parkinsons Dis       Date:  2020-01-06

Review 7.  Neuroinflammation is a key player in Parkinson's disease and a prime target for therapy.

Authors:  Li Qian; Patrick M Flood; Jau-Shyong Hong
Journal:  J Neural Transm (Vienna)       Date:  2010-06-23       Impact factor: 3.575

8.  Evidence for hydroxyl radical scavenging action of nitric oxide donors in the protection against 1-methyl-4-phenylpyridinium-induced neurotoxicity in rats.

Authors:  Rebecca Banerjee; Karuppagounder S Saravanan; Bobby Thomas; Kizhake M Sindhu; Kochupurackal P Mohanakumar
Journal:  Neurochem Res       Date:  2007-09-01       Impact factor: 3.996

9.  Potent anti-inflammatory and neuroprotective effects of TGF-beta1 are mediated through the inhibition of ERK and p47phox-Ser345 phosphorylation and translocation in microglia.

Authors:  Li Qian; Sung-Jen Wei; Dan Zhang; Xiaoming Hu; Zongli Xu; Belinda Wilson; Jamel El-Benna; Jau-Shyong Hong; Patrick M Flood
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

10.  Fish oil, melatonin and vitamin E attenuates midbrain cyclooxygenase-2 activity and oxidative stress after the administration of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine.

Authors:  Genaro Gabriel Ortiz; Fermín P Pacheco-Moisés; Víctor M Gómez-Rodríguez; Erika D González-Renovato; Erandhis D Torres-Sánchez; Ana C Ramírez-Anguiano
Journal:  Metab Brain Dis       Date:  2013-05-24       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.